Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2008, Article ID 215809, 8 pages
http://dx.doi.org/10.1155/2008/215809
Research Article

Genetic and Epigenetic Tumor Suppressor Gene Silencing Are Distinct Molecular Phenotypes Driven by Growth Promoting Mutations in Nonsmall Cell Lung Cancer

1Department of Pathology and Laboratory Medicine, Center for Environmental Health and Technology, Brown University, Providence, RI 02912, USA
2Department of Community Health, Center for Environmental Health and Technology, Brown University, Providence, RI 02912, USA
3Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
4Division of Epidemiology and Community Health, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA

Received 10 January 2008; Accepted 16 December 2008

Academic Editor: Cornelia Ulrich

Copyright © 2008 Carmen J. Marsit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2006,” CA: A Cancer Journal for Clinicians, vol. 56, no. 2, pp. 106–130, 2006. View at Google Scholar
  2. D. Schottenfeld, “Epidemiology of lung cancer,” in Lung Cancer: Principles and Practice, H. I. Pass, J. B. Mitchell, D. H. Johnson, and A. T. Turrisi, Eds., pp. 305–321, Lippincott-Raven, Philadelphia, Pa, USA, 1996. View at Google Scholar
  3. W. D. Travis, J. Linder, and B. Mackay, “Classification, histology, cytology, and electron microscopy,” in Lung Cancer: Principles and Practice, H. I. Pass, J. B. Mitchell, D. H. Johnson, and A. T. Turrisi, Eds., pp. 361–395, Lippincott-Raven, Philadelphia, Pa, USA, 1996. View at Google Scholar
  4. J. D. Minna, J. A. Roth, and A. F. Gazdar, “Focus on lung cancer,” Cancer Cell, vol. 1, no. 1, pp. 49–52, 2002. View at Publisher · View at Google Scholar
  5. C. J. Marsit, E. A. Houseman, B. C. Christensen et al., “Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors,” Cancer Research, vol. 66, no. 21, pp. 10621–10629, 2006. View at Publisher · View at Google Scholar
  6. S. A. Belinsky, “Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer,” Carcinogenesis, vol. 26, no. 9, pp. 1481–1487, 2005. View at Publisher · View at Google Scholar
  7. J. D. Minna, K. Fong, S. Zöchbauer-Müller, and A. F. Gazdar, “Molecular pathogenesis of lung cancer and potential translational applications,” The Cancer Journal, vol. 8, supplement 1, pp. S41–S46, 2002. View at Google Scholar
  8. T. Sjöblom, S. Jones, L. D. Wood et al., “The consensus coding sequences of human breast and colorectal cancers,” Science, vol. 314, no. 5797, pp. 268–274, 2006. View at Publisher · View at Google Scholar
  9. C. J. Marsit, M. Hasegawa, T. Hirao et al., “Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer,” Cancer Research, vol. 64, no. 23, pp. 8702–8707, 2004. View at Publisher · View at Google Scholar
  10. C. J. Marsit, D.-H. Kim, M. Liu et al., “Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence,” International Journal of Cancer, vol. 114, no. 2, pp. 219–223, 2005. View at Publisher · View at Google Scholar
  11. S. Zienolddiny, D. Ryberg, M. O. Arab, V. Skaug, and A. Haugen, “Loss of heterozygosity is related to p53 mutations and smoking in lung cancer,” British Journal of Cancer, vol. 84, no. 2, pp. 226–231, 2001. View at Publisher · View at Google Scholar
  12. H. H. Nelson, J. K. Wiencke, L. Gunn, J. C. Wain, D. C. Christiani, and K. T. Kelsey, “Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos,” Cancer Research, vol. 58, no. 9, pp. 1804–1807, 1998. View at Google Scholar
  13. G. Sozzi, L. Sard, L. De Gregorio et al., “Association between cigarette smoking and FHIT gene alterations in lung cancer,” Cancer Research, vol. 57, no. 11, pp. 2121–2123, 1997. View at Google Scholar
  14. K. S. Kraunz, H. H. Nelson, M. Lemos, J. J. Godleski, J. K. Wiencke, and K. T. Kelsey, “Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer,” International Journal of Cancer, vol. 118, no. 6, pp. 1364–1369, 2006. View at Publisher · View at Google Scholar
  15. S. Toyooka, R. Maruyama, K. O. Toyooka et al., “Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer,” International Journal of Cancer, vol. 103, no. 2, pp. 153–160, 2003. View at Publisher · View at Google Scholar
  16. D.-H. Kim, H. H. Nelson, J. K. Wiencke et al., “p16INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer,” Cancer Research, vol. 61, no. 8, pp. 3419–3424, 2001. View at Google Scholar
  17. K. Matsuo, H. Ito, Y. Yatabe et al., “Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese,” Cancer Science, vol. 98, no. 1, pp. 96–101, 2007. View at Publisher · View at Google Scholar
  18. I. Y. S. Tam, L. P. Chung, W. S. Suen et al., “Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features,” Clinical Cancer Research, vol. 12, no. 5, pp. 1647–1653, 2006. View at Publisher · View at Google Scholar
  19. S. Toyooka, M. Tokumo, H. Shigematsu et al., “Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers,” Cancer Research, vol. 66, no. 3, pp. 1371–1375, 2006. View at Publisher · View at Google Scholar
  20. M. Tokumo, S. Toyooka, K. Kiura et al., “The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers,” Clinical Cancer Research, vol. 11, no. 3, pp. 1167–1173, 2005. View at Google Scholar
  21. L. V. Sequist, V. A. Joshi, P. A. Jänne et al., “Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing,” The Oncologist, vol. 12, no. 1, pp. 90–98, 2007. View at Publisher · View at Google Scholar
  22. D. W. Bell, T. J. Lynch, S. M. Haserlat et al., “Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 8081–8092, 2005. View at Publisher · View at Google Scholar
  23. Y. Tomizawa, H. Iijima, N. Sunaga et al., “Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer,” Clinical Cancer Research, vol. 11, no. 19, part 1, pp. 6816–6822, 2005. View at Publisher · View at Google Scholar
  24. T. Mitsudomi, T. Kosaka, H. Endoh et al., “Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence,” Journal of Clinical Oncology, vol. 23, no. 11, pp. 2513–2520, 2005. View at Publisher · View at Google Scholar
  25. H. H. Nelson, D. C. Christiani, E. J. Mark, J. K. Wiencke, J. C. Wain, and K. T. Kelsey, “Implications and prognostic value of K-ras mutation for early-stage lung cancer in women,” Journal of the National Cancer Institute, vol. 91, no. 23, pp. 2032–2038, 1999. View at Publisher · View at Google Scholar
  26. T. Hirao, H. H. Nelson, T. D. S. Ashok et al., “Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer,” Cancer Research, vol. 61, no. 2, pp. 612–615, 2001. View at Google Scholar
  27. J. G. Herman, J. R. Graff, S. Myöhänen, B. D. Nelkin, and S. B. Baylin, “Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821–9826, 1996. View at Publisher · View at Google Scholar
  28. C. J. Marsit, M. R. Karagas, A. Andrew et al., “Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer,” Cancer Research, vol. 65, no. 16, pp. 7081–7085, 2005. View at Publisher · View at Google Scholar
  29. M. van Engeland, G. M. J. M. Roemen, M. Brink et al., “K-ras mutations and RASSF1A promoter methylation in colorectal cancer,” Oncogene, vol. 21, no. 23, pp. 3792–3795, 2002. View at Publisher · View at Google Scholar
  30. A. K. Virmani, A. Rathi, U. G. Sathyanarayana et al., “Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas,” Clinical Cancer Research, vol. 7, no. 7, pp. 1998–2004, 2001. View at Google Scholar
  31. A. Virmani, A. Rathi, K. Sugio et al., “Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer,” International Journal of Cancer, vol. 106, no. 2, pp. 198–204, 2003. View at Publisher · View at Google Scholar
  32. U. G. Sathyanarayana, R. Maruyama, A. Padar et al., “Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes,” Cancer Research, vol. 64, no. 4, pp. 1425–1430, 2004. View at Publisher · View at Google Scholar
  33. H. Suzuki, D. N. Watkins, K.-W. Jair et al., “Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer,” Nature Genetics, vol. 36, no. 4, pp. 417–422, 2004. View at Publisher · View at Google Scholar
  34. S. Zöchbauer-Müller, K. M. Fong, A. K. Virmani, J. Geradts, A. F. Gazdar, and J. D. Minna, “Aberrant promoter methylation of multiple genes in non-small cell lung cancers,” Cancer Research, vol. 61, no. 1, pp. 249–255, 2001. View at Google Scholar
  35. S. Toyooka, H. I. Pass, N. Shivapurkar et al., “Aberrant methylation and simian virus 40?tag sequences in malignant mesothelioma,” Cancer Research, vol. 61, no. 15, pp. 5727–5730, 2001. View at Google Scholar
  36. A. O.-O. Chan, R. R. Broaddus, P. S. Houlihan, J.-P. J. Issa, S. R. Hamilton, and A. Rashid, “CpG island methylation in aberrant crypt foci of the colorectum,” The American Journal of Pathology, vol. 160, no. 5, pp. 1823–1830, 2002. View at Google Scholar
  37. E. Evron, C. B. Umbricht, D. Korz et al., “Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation,” Cancer Research, vol. 61, no. 6, pp. 2782–2787, 2001. View at Google Scholar
  38. K. Yamashita, K. Mimori, H. Inoue, M. Mori, and D. Sidransky, “A tumor-suppressive role for trypsin in human cancer progression,” Cancer Research, vol. 63, no. 20, pp. 6575–6578, 2003. View at Google Scholar
  39. C. A. Eads, K. D. Danenberg, K. Kawakami et al., “MethyLight: a high-throughput assay to measure DNA methylation,” Nucleic Acids Research, vol. 28, no. 8, article e32, pp. 1–8, 2000. View at Publisher · View at Google Scholar
  40. R. K. Hambleton and L. L. Cook, “Latent trait models and their use in analysis of educational testing data,” Journal of Educational Measurement, vol. 14, no. 2, pp. 75–96, 1977. View at Publisher · View at Google Scholar
  41. B. N. Sánchez, E. Budtz-Jørgensen, L. M. Ryan, and H. Hu, “Structural equation models: a review with applications to environmental epidemiology,” Journal of the American Statistical Association, vol. 100, no. 472, pp. 1443–1455, 2005. View at Google Scholar
  42. E. A. Houseman, C. J. Marsit, M. Karagas, and L. M. Ryan, “Penalized item response theory models: application to epigenetic alterations in bladder cancer,” Biometrics, vol. 63, no. 4, pp. 1269–1277, 2007. View at Publisher · View at Google Scholar
  43. T. Takahashi, H. Shigematsu, N. Shivapurkar et al., “Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers,” International Journal of Cancer, vol. 118, no. 4, pp. 924–931, 2006. View at Publisher · View at Google Scholar
  44. M. Toyota, N. Ahuja, H. Suzuki et al., “Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype,” Cancer Research, vol. 59, no. 21, pp. 5438–5442, 1999. View at Google Scholar
  45. H. H. Nelson, D. C. Christiani, J. K. Wiencke, E. J. Mark, J. C. Wain, and K. T. Kelsey, “K-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis,” Cancer Research, vol. 59, no. 18, pp. 4570–4573, 1999. View at Google Scholar
  46. D. J. Weisenberger, K. D. Siegmund, M. Campan et al., “CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer,” Nature Genetics, vol. 38, no. 7, pp. 787–793, 2006. View at Publisher · View at Google Scholar
  47. R Development Core Team, “R: a language and environment for statistical computing,” R Foundation for Statistical Computing, Vienna, Austria, 2005.
  48. W. S. Samowitz, H. Albertsen, J. Herrick et al., “Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer,” Gastroenterology, vol. 129, no. 3, pp. 837–845, 2005. View at Publisher · View at Google Scholar
  49. M. Toyota, N. Ahuja, M. Ohe-Toyota, J. G. Herman, S. B. Baylin, and J.-P. J. Issa, “CpG island methylator phenotype in colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 15, pp. 8681–8686, 1999. View at Publisher · View at Google Scholar
  50. M. Toyota, M. Ohe-Toyota, N. Ahuja, and J.-P. J. Issa, “Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 710–715, 2000. View at Publisher · View at Google Scholar
  51. K. Yamashita, T. Dai, Y. Dai, F. Yamamoto, and M. Perucho, “Genetics supersedes epigenetics in colon cancer phenotype,” Cancer Cell, vol. 4, no. 2, pp. 121–131, 2003. View at Publisher · View at Google Scholar
  52. S. A. Belinsky, W. A. Palmisano, F. D. Gilliland et al., “Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers,” Cancer Research, vol. 62, no. 8, pp. 2370–2377, 2002. View at Google Scholar
  53. H. Rajagopalan, A. Bardelli, C. Lengauer, K. W. Kinzler, B. Vogelstein, and V. E. Velculescu, “Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status,” Nature, vol. 418, no. 6901, p. 934, 2002. View at Publisher · View at Google Scholar